Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-siPSMA-14 is a silicon-based, fluorine-18-labeled radiopharmaceutical tracer targeting prostate-specific membrane antigen (PSMA). It was developed by the Technical University of Munich in collaboration with Ulm University and Scintomics. The tracer utilizes a silicon-fluoride acceptor (SiFA) moiety, which allows for a simplified, fast, and scalable one-step isotopic exchange (18F-for-19F) radiolabeling process at room temperature without the need for complex purification or high-temperature heating. 18F-siPSMA-14 is designed for positron emission tomography (PET) imaging of prostate cancer, enabling high-contrast visualization of primary and metastatic lesions without requiring forced diuresis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18F-siPSMA-14.